Personalis said CMS expanded Medicare coverage for its NeXT Personal minimal residual disease (MRD) test to include monitoring response to neoadjuvant therapy in stages II to III triple-negative or HER2-positive breast cancer. The decision cites evidence from the PREDICT-DNA prospective study and marks the fourth Medicare coverage determination for the whole-genome sequencing-based, tumor-informed assay. The company previously secured coverage for immunotherapy monitoring across late-stage solid tumors, plus recurrence monitoring in stages II to III breast cancer and stages I to III non-small cell lung cancer. Personalis positioned the latest approval as moving NeXT Personal into active treatment management decisions across the breast cancer continuum. Shares rose nearly 9% in premarket trading following the CMS update, underscoring investor focus on payor adoption as MRD testing shifts toward routine clinical workflows.